Bibliography for INIM0031: Neoplasia and its Treatment BETA

Ajila, Vidya et al. ‘Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck’. Journal of Sexually Transmitted Diseases 2015 (2015): 1–5. Web.

Barrett, David M., Stephan A. Grupp, and Carl H. June. ‘Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street’. The Journal of Immunology 195.3 (2015): 755–761. Web.

de Martel, Catherine et al. ‘Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis’. The Lancet Oncology 13.6 (2012): 607–615. Web.

Ecker, Dawn M, Susan Dana Jones, and Howard L Levine. ‘The Therapeutic Monoclonal Antibody Market’. mAbs 7.1 (2015): 9–14. Web.

Gill, Saar, and Carl H. June. ‘Going Viral: Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies’. Immunological Reviews 263.1 (2015): 68–89. Web.

Grupp, Stephan A. et al. ‘Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia’. New England Journal of Medicine 368.16 (2013): 1509–1518. Web.

Hanahan, Douglas, and Robert A Weinberg. ‘The Hallmarks of Cancer’. Cell 100.1 (2000): 57–70. Web.

Hodi, F. Stephen et al. ‘Improved Survival with Ipilimumab in Patients with Metastatic Melanoma’. New England Journal of Medicine 363.8 (2010): 711–723. Web.

Jeggo, Penny A., Laurence H. Pearl, and Antony M. Carr. ‘DNA Repair, Genome Stability and Cancer: A Historical Perspective’. Nature Reviews Cancer 16.1 (2015): 35–42. Web.

Kaufman, Howard L., Frederick J. Kohlhapp, and Andrew Zloza. ‘Oncolytic Viruses: A New Class of Immunotherapy Drugs’. Nature Reviews Drug Discovery 14.9 (2015): 642–662. Web.

Klebanoff, Christopher A, Steven A Rosenberg, and Nicholas P Restifo. ‘Prospects for Gene-Engineered T Cell Immunotherapy for Solid Cancers’. Nature Medicine 22.1 (2016): 26–36. Web.

Koebel, Catherine M. et al. ‘Adaptive Immunity Maintains Occult Cancer in an Equilibrium State’. Nature 450.7171 (2007): 903–907. Web.

Larson, Christopher et al. ‘Going Viral: A Review of Replication-Selective Oncolytic Adenoviruses’. Oncotarget 6.24 (2015): n. pag. Web.

Lazebnik, Yuri. ‘What Are the Hallmarks of Cancer?’ Nature Reviews Cancer 10.4 (2010): 232–233. Web.

Lingyun Geng. ‘Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Experimental and Clinical Developments’. International Journal of Clinical and Experimental Medicine 8.9 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/>.

Matsuoka, M, and K-T Jeang. ‘Human T-Cell Leukemia Virus Type 1 (HTLV-1) and Leukemic Transformation: Viral Infectivity, Tax, HBZ and Therapy’. Oncogene 30.12 (2011): 1379–1389. Web.

Morris, Emma C., and Hans J. Stauss. ‘Optimizing T-Cell Receptor Gene Therapy for Hematologic Malignancies’. Blood 127.26 (2016): 3305–3311. Web.

Palucka, Karolina, and Jacques Banchereau. ‘Cancer Immunotherapy via Dendritic Cells’. Nature Reviews Cancer 12.4 (2012): 265–277. Web.

Pierangeli, A., G. Antonelli, and G. Gentile. ‘Immunodeficiency-Associated Viral Oncogenesis’. Clinical Microbiology and Infection 21.11 (2015): 975–983. Web.

Reichert, Janice M. ‘Antibodies to Watch in 2016’. mAbs 8.2 (2016): 197–204. Web.

---. ‘Antibodies to Watch in 2017’. mAbs 9.2 (2017): 167–181. Web.

---. ‘Marketed Therapeutic Antibodies Compendium’. mAbs 4.3 (2012): 413–415. Web.

Restifo, Nicholas P., Mark E. Dudley, and Steven A. Rosenberg. ‘Adoptive Immunotherapy for Cancer: Harnessing the T Cell Response’. Nature Reviews Immunology 12.4 (2012): 269–281. Web.

Robbins, Paul F. et al. ‘Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1’. Journal of Clinical Oncology 29.7 (2011): 917–924. Web.

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. ‘Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion’. Science 331.6024 (2011): 1565–1570. Web. <http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents>.

Roos, Wynand P., Adam D. Thomas, and Bernd Kaina. ‘DNA Damage and the Balance between Survival and Death in Cancer Biology’. Nature Reviews Cancer 16.1 (2015): 20–33. Web.

Russell, Stephen J, Kah-Whye Peng, and John C Bell. ‘Oncolytic Virotherapy’. Nature Biotechnology 30.7 (2012): 658–670. Web.

Schinzari, V., V. Barnaba, and S. Piconese. ‘Chronic Hepatitis B Virus and Hepatitis C Virus Infections and Cancer: Synergy between Viral and Host Factors’. Clinical Microbiology and Infection 21.11 (2015): 969–974. Web.

Schumacher, T. N., and R. D. Schreiber. ‘Neoantigens in Cancer Immunotherapy’. Science 348.6230 (2015): 69–74. Web.

Shankaran, Vijay et al. ‘IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity’. Nature 410.6832 (2001): 1107–1111. Web.

Spurgeon, Megan E., and Paul F. Lambert. ‘Merkel Cell Polyomavirus: A Newly Discovered Human Virus with Oncogenic Potential’. Virology 435.1 (2013): 118–130. Web.

Topalian, Suzanne L. et al. ‘Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer’. New England Journal of Medicine 366.26 (2012): 2443–2454. Web.

Varghese, Susan, and Samuel D Rabkin. ‘Oncolytic Herpes Simplex Virus Vectors for Cancer Virotherapy’. Cancer Gene Therapy 9.12 (2002): 967–978. Web.

Weinberg, Robert A. The Biology of Cancer. 2nd ed. New York: Garland Science, 2014. Print.

Weiss, Robin A., and Peter K. Vogt. ‘100 Years of Rous Sarcoma Virus’. The Journal of Experimental Medicine 208.12 (2011): 2351–2355. Web.

Wendzicki, Justin A, Patrick S Moore, and Yuan Chang. ‘Large T and Small T Antigens of Merkel Cell Polyomavirus’. Current Opinion in Virology 11 (2015): 38–43. Web.

zur Hausen, Harald. ‘Papillomaviruses in the Causation of Human Cancers — a Brief Historical Account’. Virology 384.2 (2009): 260–265. Web.